首页 > 最新文献

Journal of Thoracic Oncology最新文献

英文 中文
Appreciate the Past, but Embrace the Present and Future: Historical Versus Modern Data of Stereotactic Ablative Radiotherapy for Early-Stage NSCLC 欣赏过去,拥抱现在和未来:立体定向消融放疗治疗早期非小细胞肺癌的历史与现代数据对比
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.009
Joe Y. Chang MD, PhD, FASTRO, FACR, Vivek Verma MD
{"title":"Appreciate the Past, but Embrace the Present and Future: Historical Versus Modern Data of Stereotactic Ablative Radiotherapy for Early-Stage NSCLC","authors":"Joe Y. Chang MD, PhD, FASTRO, FACR, Vivek Verma MD","doi":"10.1016/j.jtho.2024.08.009","DOIUrl":"10.1016/j.jtho.2024.08.009","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1486-1488"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC 等位基因不再是涉及 NSCLC 精准肿瘤学疗法的 3 期随机对照试验伦理评估的主要考虑因素
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.023
Jennifer W. Carlisle MD, Rebecca D. Pentz PhD, Suresh S. Ramalingam MD
{"title":"Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC","authors":"Jennifer W. Carlisle MD, Rebecca D. Pentz PhD, Suresh S. Ramalingam MD","doi":"10.1016/j.jtho.2024.08.023","DOIUrl":"10.1016/j.jtho.2024.08.023","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1509-1511"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Board of Directors 董事会
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/S1556-0864(24)02364-5
{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(24)02364-5","DOIUrl":"10.1016/S1556-0864(24)02364-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness 对 ALK 酪氨酸激酶抑制剂研究方法的严格评估:处理混杂因素和统计稳健性
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.020
Wenqin Wang PhD, Xiangzhi Li PhD, Dan Shan MD
{"title":"Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness","authors":"Wenqin Wang PhD, Xiangzhi Li PhD, Dan Shan MD","doi":"10.1016/j.jtho.2024.08.020","DOIUrl":"10.1016/j.jtho.2024.08.020","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e64-e65"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3 用于检测治疗期间表皮生长因子受体突变阳性晚期非小细胞肺癌进展的循环肿瘤 DNA 纵向分析:来自 FLAURA 和 AURA3 的数据。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.07.008
Jhanelle E. Gray MD , Aleksandra Markovets PhD , Thanyanan Reungwetwattana MD, MSc , Margarita Majem MD, PhD , Naoyuki Nogami MD, PhD , Nir Peled MD, PhD , Jong-Seok Lee MD , Byoung Chul Cho MD, PhD , Busayamas Chewaskulyong MD , Tom John MD, PhD , Ji-Youn Han MD, PhD , Martin Sebastian MD , Alexander Todd MSc , Yuri Rukazenkov MD, PhD , Carl Barrett PhD , Juliann Chmielecki PhD , Siow Ming Lee PhD, FRCP , Suresh S. Ramalingam MD , Ryan Hartmaier PhD

Introduction

EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.

Methods

This was a retrospective, exploratory ctDNA analysis in two phase 3 trials (FLAURA, NCT02296125; AURA3, NCT02151981). Patients had treatment-naïve (FLAURA) or EGFR-TKI pre-treated (AURA3) advanced NSCLC with EGFR mutations and on-study PD (RECIST [Response Evaluation Criteria in Solid Tumors]), with a baseline ctDNA result and EGFR-mutation ctDNA monitoring beyond Cycle 3 Day 1. Patients received osimertinib versus comparator EGFR-TKIs (FLAURA) or chemotherapy (AURA3). Outcomes included time from ctDNA PD to RECIST PD and the first subsequent treatment (FLAURA only).

Results

Circulating tumor DNA PD preceded or co-occurred with RECIST-defined PD in 93 out of 146 patients (64%) in FLAURA and 82 out of 146 patients (56%) in AURA3. Median time from ctDNA PD to RECIST-defined PD (mo) was 3.4 and 2.6 in the osimertinib and comparator EGFR-TKI arms (FLAURA) and 2.8 and 1.5 in the osimertinib and chemotherapy arms (AURA3). In FLAURA, the median time from ctDNA PD to the first subsequent treatment (mo) was 6.0 and 4.7 in the osimertinib (n = 51) and comparator EGFR-TKI arms (n = 70).

Conclusions

Among patients with EGFR mutation-positive advanced NSCLC receiving EGFR-TKI or chemotherapy with ctDNA data and RECIST-defined PD, ctDNA PD preceded/co-occurred with RECIST-defined PD in approximately 60% of cases. Longitudinal ctDNA monitoring may detect PD before radiologic PD.
导言:表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)致敏突变和耐药突变可通过循环肿瘤DNA(ctDNA)在血浆中检测到。本分析旨在确定纵向表皮生长因子受体突变ctDNA检测是否能在放射学检测之前发现进展性疾病(PD):这是对两项三期试验(FLAURA,NCT02296125;AURA3,NCT02151981)进行的一项回顾性、探索性ctDNA分析。患者均为未经治疗(FLAURA)或EGFR-TKI预处理(AURA3)的晚期非小细胞肺癌(NSCLC)患者,具有EGFR突变和研究中PD(RECIST),基线ctDNA结果和第3周期第1天后的EGFR突变ctDNA监测。患者接受奥希替尼与对比EGFR-TKIs(FLAURA)或化疗(AURA3)。结果包括从ctDNA PD到RECIST PD的时间,以及到首次后续治疗(FST;仅FLAURA)的时间。结果:在FLAURA中,93/146(64%)例患者的ctDNA PD先于/并发于RECIST定义的PD;在AURA3中,82/146(56%)例患者的ctDNA PD先于/并发于RECIST定义的PD。从ctDNA PD到RECIST定义的PD的中位时间(月),在奥希替尼和对比药EGFR-TKI治疗组(FLAURA)分别为3.4和2.6,在奥希替尼和化疗组(AURA3)分别为2.8和1.5。在FLAURA中,从ctDNA PD到FST的中位时间(月)分别为6.0个月和4.7个月,奥希替尼组(n = 51)和EGFR-TKI对照组(n = 70)分别为6.0个月和4.7个月:在接受表皮生长因子受体突变阳性晚期NSCLC患者中,接受EGFR-TKI或化疗且有ctDNA数据和RECIST定义的PD的患者中,约60%的病例在RECIST定义的PD之前/同时出现ctDNA PD。ctDNA纵向监测可在放射学PD之前发现PD。
{"title":"Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3","authors":"Jhanelle E. Gray MD ,&nbsp;Aleksandra Markovets PhD ,&nbsp;Thanyanan Reungwetwattana MD, MSc ,&nbsp;Margarita Majem MD, PhD ,&nbsp;Naoyuki Nogami MD, PhD ,&nbsp;Nir Peled MD, PhD ,&nbsp;Jong-Seok Lee MD ,&nbsp;Byoung Chul Cho MD, PhD ,&nbsp;Busayamas Chewaskulyong MD ,&nbsp;Tom John MD, PhD ,&nbsp;Ji-Youn Han MD, PhD ,&nbsp;Martin Sebastian MD ,&nbsp;Alexander Todd MSc ,&nbsp;Yuri Rukazenkov MD, PhD ,&nbsp;Carl Barrett PhD ,&nbsp;Juliann Chmielecki PhD ,&nbsp;Siow Ming Lee PhD, FRCP ,&nbsp;Suresh S. Ramalingam MD ,&nbsp;Ryan Hartmaier PhD","doi":"10.1016/j.jtho.2024.07.008","DOIUrl":"10.1016/j.jtho.2024.07.008","url":null,"abstract":"<div><h3>Introduction</h3><div>EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal <em>EGFR</em>-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.</div></div><div><h3>Methods</h3><div>This was a retrospective, exploratory ctDNA analysis in two phase 3 trials (FLAURA, NCT02296125; AURA3, NCT02151981). Patients had treatment-naïve (FLAURA) or EGFR-TKI pre-treated (AURA3) advanced NSCLC with <em>EGFR</em> mutations and on-study PD (RECIST [Response Evaluation Criteria in Solid Tumors]), with a baseline ctDNA result and <em>EGFR</em>-mutation ctDNA monitoring beyond Cycle 3 Day 1. Patients received osimertinib versus comparator EGFR-TKIs (FLAURA) or chemotherapy (AURA3). Outcomes included time from ctDNA PD to RECIST PD and the first subsequent treatment (FLAURA only).</div></div><div><h3>Results</h3><div>Circulating tumor DNA PD preceded or co-occurred with RECIST-defined PD in 93 out of 146 patients (64%) in FLAURA and 82 out of 146 patients (56%) in AURA3. Median time from ctDNA PD to RECIST-defined PD (mo) was 3.4 and 2.6 in the osimertinib and comparator EGFR-TKI arms (FLAURA) and 2.8 and 1.5 in the osimertinib and chemotherapy arms (AURA3). In FLAURA, the median time from ctDNA PD to the first subsequent treatment (mo) was 6.0 and 4.7 in the osimertinib (n = 51) and comparator EGFR-TKI arms (n = 70).</div></div><div><h3>Conclusions</h3><div>Among patients with <em>EGFR</em> mutation-positive advanced NSCLC receiving EGFR-TKI or chemotherapy with ctDNA data and RECIST-defined PD, ctDNA PD preceded/co-occurred with RECIST-defined PD in approximately 60% of cases. Longitudinal ctDNA monitoring may detect PD before radiologic PD.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1525-1538"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic Body Radiation Therapy Without Pathologic Diagnosis: A Risky Approach 未经病理诊断的立体定向体放射治疗:有风险的方法
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.006
Zhaoning Li MD, Xian Ye MD
{"title":"Stereotactic Body Radiation Therapy Without Pathologic Diagnosis: A Risky Approach","authors":"Zhaoning Li MD,&nbsp;Xian Ye MD","doi":"10.1016/j.jtho.2024.08.006","DOIUrl":"10.1016/j.jtho.2024.08.006","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e71-e72"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC 深入探讨立体定向体外放射治疗 I 期 NSCLC 后相关急性毒性和 90 天死亡率的荷兰预测模型
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.09.1427
Peter S.N. van Rossum MD, PhD, Nienke Wolfhagen MD, Ronald A.M. Damhuis PhD, José S.A. Belderbos MD, PhD
{"title":"An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC","authors":"Peter S.N. van Rossum MD, PhD,&nbsp;Nienke Wolfhagen MD,&nbsp;Ronald A.M. Damhuis PhD,&nbsp;José S.A. Belderbos MD, PhD","doi":"10.1016/j.jtho.2024.09.1427","DOIUrl":"10.1016/j.jtho.2024.09.1427","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e74-e77"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]” 对 "简要报告 "的勘误:加拿大癌症试验组 IND.227:pembrolizumab 用于晚期恶性胸膜间皮瘤患者的 II 期随机研究(NCT02784171)。[胸腔肿瘤学杂志》第 18 卷第 6 期:813-819]"。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.017
Maria Carmela Piccirillo MD , Quincy Chu MD , Penelope Bradbury MD , Wei Tu PhD , Courtney H. Coschi MD, PhD , Federica Grosso MD , Marie Florescu MD , Manlio Mencoboni MD , John R. Goffin MD , Maria Pagano MD , Fortunato Ciardiello MD, PhD , Fabiana Letizia Cecere MD , Mark Vincent MD , Roberto Ferrara MD , David E. Dawe MD, MSc , Desiree Hao MD , Christopher W. Lee MD , Alessandro Morabito MD , Cesare Gridelli MD , Luigi Cavanna MD , Scott A. Laurie MD
{"title":"Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”","authors":"Maria Carmela Piccirillo MD ,&nbsp;Quincy Chu MD ,&nbsp;Penelope Bradbury MD ,&nbsp;Wei Tu PhD ,&nbsp;Courtney H. Coschi MD, PhD ,&nbsp;Federica Grosso MD ,&nbsp;Marie Florescu MD ,&nbsp;Manlio Mencoboni MD ,&nbsp;John R. Goffin MD ,&nbsp;Maria Pagano MD ,&nbsp;Fortunato Ciardiello MD, PhD ,&nbsp;Fabiana Letizia Cecere MD ,&nbsp;Mark Vincent MD ,&nbsp;Roberto Ferrara MD ,&nbsp;David E. Dawe MD, MSc ,&nbsp;Desiree Hao MD ,&nbsp;Christopher W. Lee MD ,&nbsp;Alessandro Morabito MD ,&nbsp;Cesare Gridelli MD ,&nbsp;Luigi Cavanna MD ,&nbsp;Scott A. Laurie MD","doi":"10.1016/j.jtho.2024.08.017","DOIUrl":"10.1016/j.jtho.2024.08.017","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1578-1579"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma IASLC 间皮瘤分期项目:关于即将出版的胸膜间皮瘤 TNM 分类第 9 版中 M 级描述符的建议。
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.022
Hedy L. Kindler MD , Adam Rosenthal MS , Dorothy J. Giroux MS , Anna K. Nowak M.B.B.S., PhD , Andrea Billè MD, PhD , Ritu R. Gill M.B.B.S., MPH , Harvey Pass MD , David Rice MD , Robert T. Ripley MD , Andrea Wolf MD, MPH , Kevin G. Blyth MD , Susanna Cedres MD, PhD , Valerie Rusch MD , Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions

Introduction

The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.

Methods

Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.

Results

Of 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (p < 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, p = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, p = 0.45).

Conclusions

This evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.
导言:国际肺癌研究协会(IASLC)开发了一个全球多中心数据库,为第9版胸膜间皮瘤(PM)的肿瘤结节转移(TNM)分类提出循证修订建议。本研究分析了M分类,以验证第8版M分类的建议:方法:病例以电子方式提交,或从现有的机构数据库中调取经组织学或细胞学确诊的胸膜间皮瘤患者的资料。对于诊断时为M1疾病的患者,报告八个器官系统中每个系统是否存在转移灶以及转移灶的数量(单个或多个)。总生存期(OS)采用 Kaplan-Meier 法计算。OS 的差异通过对数秩检验进行评估:在提交的 7,338 个病例中,3,598 个符合条件,3,221 个有足够数据进行临床分期;228 个病例(7%)为 M1。与 M0 患者相比,M1 患者的中位总估计生存率较低:分别为 10.5 个月和 21.5 个月(p 结论:这是一项基于证据的 M 级分类分析:对 PM 的 M 级分类进行的循证分析符合第 8 版的 M 级描述。第9版的间皮瘤M分类没有提出任何变化。
{"title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","authors":"Hedy L. Kindler MD ,&nbsp;Adam Rosenthal MS ,&nbsp;Dorothy J. Giroux MS ,&nbsp;Anna K. Nowak M.B.B.S., PhD ,&nbsp;Andrea Billè MD, PhD ,&nbsp;Ritu R. Gill M.B.B.S., MPH ,&nbsp;Harvey Pass MD ,&nbsp;David Rice MD ,&nbsp;Robert T. Ripley MD ,&nbsp;Andrea Wolf MD, MPH ,&nbsp;Kevin G. Blyth MD ,&nbsp;Susanna Cedres MD, PhD ,&nbsp;Valerie Rusch MD ,&nbsp;Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions","doi":"10.1016/j.jtho.2024.08.022","DOIUrl":"10.1016/j.jtho.2024.08.022","url":null,"abstract":"<div><h3>Introduction</h3><div>The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.</div></div><div><h3>Methods</h3><div>Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.</div></div><div><h3>Results</h3><div>Of 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (<em>p</em> &lt; 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, <em>p</em> = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, <em>p</em> = 0.45).</div></div><div><h3>Conclusions</h3><div>This evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1564-1577"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Cancer in Romania 罗马尼亚的肺癌
IF 21 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.003
Gheorghe-Emilian Olteanu MD, PhD , Alon Vigdorovits MD , Robert Alexandru Barna MD , Laura Mazilu MD, PhD , Veronica Manolache MD , Vladimir Preoteasa MD , Sebastian Curcean MD , Andrei Roman MD, PhD , Natalia Motas MD, PhD , Mircea Dediu MD, PhD , Diana N. Ionescu MD, PhD
{"title":"Lung Cancer in Romania","authors":"Gheorghe-Emilian Olteanu MD, PhD ,&nbsp;Alon Vigdorovits MD ,&nbsp;Robert Alexandru Barna MD ,&nbsp;Laura Mazilu MD, PhD ,&nbsp;Veronica Manolache MD ,&nbsp;Vladimir Preoteasa MD ,&nbsp;Sebastian Curcean MD ,&nbsp;Andrei Roman MD, PhD ,&nbsp;Natalia Motas MD, PhD ,&nbsp;Mircea Dediu MD, PhD ,&nbsp;Diana N. Ionescu MD, PhD","doi":"10.1016/j.jtho.2024.08.003","DOIUrl":"10.1016/j.jtho.2024.08.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1492-1503"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Thoracic Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1